3 documents found, page 1 of 1
Repurposing the β3-adrenergic receptor agonist Mirabegron in patients with stru...
Balligand, Jean-Luc; Brito, Dulce; Brosteanu, Oana; Casadei, Barbara; Depoix, Christophe; Edelmann, Frank; Ferreira, Vanessa; Filippatos, GerasimosImportance: Left ventricular (LV) hypertrophy contributes to the onset and progression of heart failure (HF), particularly for patients with pre-HF (stage B) for whom no treatment has yet proven effective to prevent transition to overt HF (stage C). The β3-adrenergic receptors (β3ARs) may represent a new target, as their activation attenuates LV remodeling. Objective: To determine whether activation of β3ARs by...
Standardised exercise prescription for patients with chronic coronary syndrome ...
Hansen, Dominique; Beckers, Paul; Neunhäuserer, Daniel; Bjarnason-Wehrens, Birna; Piepoli, Massimo F.; Rauch, Bernhard; Völler, Heinz; Corrà, UgoWhereas exercise training, as part of multidisciplinary rehabilitation, is a key component in the management of patients with chronic coronary syndrome (CCS) and/or congestive heart failure (CHF), physicians and exercise professionals disagree among themselves on the type and characteristics of the exercise to be prescribed to these patients, and the exercise prescriptions are not consistent with the internatio...
Rationale and design of a multicentre, randomized,placebo-controlled trial of m...
Pouleur, Anne-Catherine; Anker, Stefan; Brito, Dulce; Brosteanu, Oana; Hasenclever, Dirk; Casadei, Barbara; Edelmann, Frank; Filippatos, GerasimosAims: Progressive left ventricular (LV) remodelling with cardiac myocyte hypertrophy, myocardial fibrosis, and endothelial dysfunction plays a key role in the onset and progression of heart failure with preserved ejection fraction. The Beta3‐LVH trial will test the hypothesis that the β3 adrenergic receptor agonist mirabegron will improve LV hypertrophy and diastolic function in patients with hypertensive struc...